{"symbol":"BMY","fiscalQuarter":"Q2-2015","reportDate":"2015-07-23","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q2-2015","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS \u2014 Stock Down 1.63%","keyNumbers":[{"metric":"EPS","actual":"$0.53","expected":"N/A","surprise":"+52.74%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key therapeutic areas.","They acknowledged ongoing challenges in the market but expressed confidence in their pipeline."],"summary":"Overall, management conveyed a positive outlook on their product performance despite market challenges. They emphasized the importance of their ongoing research and development efforts."},"guidanceChanges":{"summary":"No forward guidance was provided during this earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a strong EPS beat, which indicates better-than-expected profitability. However, the stock fell by 1.63%, likely due to a lack of revenue details and no updated guidance. Investors may be cautious as the company navigates market challenges while focusing on its product pipeline.","metaDescription":"Bristol Myers Squibb (BMY) Q2 2015 earnings: EPS beat by 52.74%. Stock down 1.63%. Full breakdown."}}